

Levetiracetam XR Drug Use Criteria

Created: September 2015

Revised: April 2019

Includes:

Keppra XR®

Levetiracetam XR

**Please note generic Levetiracetam immediate release tablets are available on the Advanced Health formulary without a prior authorization.*

GUIDELINE FOR USE:

Initial Request:

1. Is the patient being treated for epilepsy or a seizure disorder?
 - a. If yes, go to 2
 - b. If no, deny as criteria not met. The use of this medication is reserved for members with FDA approved indications of epilepsy or seizure disorder. Off-label use of medication is not a covered benefit on OHP.
2. Does the patient have any contraindications to levetiracetam therapy?
 - a. If yes, deny as not meeting criteria. Off-label use of medication is not a covered benefit on OHP.
 - b. If no, go to 3
3. Is the dose prescribed consistent with the FDA approved prescribing information?
 - a. If yes, go to 4
 - b. If no, deny as not meeting criteria. Off-label use of medication is not a covered benefit on OHP.
4. Has the patient failed an adequate trial of immediate-release levetiracetam?
 - a. If yes, approve for requested duration of therapy up to 1 year.
 - b. If no, deny as not meeting criteria. A trial of immediate-release levetiracetam is recommended prior to the use of levetiracetam XR.

Renewal Request:

1. Is the patient stable on the prescribed regimen and are they filling medication consistently?
 - a. If yes, approve for requested duration of therapy up to 1 year as continued therapy.
 - b. If no, approve for one month and coordinate with provider regarding therapy change or adherence strategies to optimize patient outcome.

Approved by Managed Care 7/08/2011

Approved by Advanced Health Pharmacy and Therapeutics Committee 4/22/2019

Rationale:

To ensure use consistent with FDA approved package insert and trial of least costly alternative agent.

FDA Approved Indication:

Adjunctive therapy in the treatment of partial onset seizure in patients 12 years of age and older with epilepsy.

Mechanism of Action:

The precise mechanism of action by which levetiracetam exerts its antiepileptic effect is unknown.

Dosing:

Initial treatment with a dose of 1000mg once daily. Increase by 1000mg every 2 weeks to a maximum recommended dose of 3000mg once daily.

Contraindications:

- Known hypersensitivity to levetiracetam

References:

1. Keppra XR© Package insert. Revised date April 2017.